SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nastech [NSTK] -Sm & Lrg Molecule Intranasal drug delivery
MRNA 43.81-6.5%3:25 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI7/13/2006 10:59:54 PM
   of 80
 
From NSTK’s PR:

>If Nastech is not successful at keeping this application as an ANDA then a 505(b)(2) NDA may be pursued.<

This strikes me as a questionable pursuit. If approved as a 505b2 drug, NSTK’s intranasal calcitonin would not be substitutable for Miacalcin and would need a full-fledged salesforce. I doubt that Par (NSTK’s partner) would be able to make this product a big seller and hence the outcome would more than likely be negligible profits for NSTK.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News